S&P 500   5,000.83 (-0.21%)
DOW   37,915.40 (+0.37%)
QQQ   420.87 (-0.60%)
AAPL   165.35 (-1.01%)
MSFT   402.51 (-0.44%)
META   491.71 (-2.01%)
GOOGL   154.77 (-0.79%)
AMZN   177.68 (-0.86%)
TSLA   148.64 (-0.86%)
NVDA   838.49 (-0.97%)
AMD   152.74 (-1.51%)
NIO   3.87 (-3.25%)
BABA   68.78 (-0.15%)
T   16.38 (+0.31%)
F   12.16 (+0.83%)
MU   109.98 (-1.74%)
GE   152.66 (-0.18%)
CGC   8.20 (+4.73%)
DIS   111.97 (-0.41%)
AMC   3.12 (+6.85%)
PFE   25.40 (+0.04%)
PYPL   62.12 (+0.03%)
XOM   120.10 (+1.33%)
S&P 500   5,000.83 (-0.21%)
DOW   37,915.40 (+0.37%)
QQQ   420.87 (-0.60%)
AAPL   165.35 (-1.01%)
MSFT   402.51 (-0.44%)
META   491.71 (-2.01%)
GOOGL   154.77 (-0.79%)
AMZN   177.68 (-0.86%)
TSLA   148.64 (-0.86%)
NVDA   838.49 (-0.97%)
AMD   152.74 (-1.51%)
NIO   3.87 (-3.25%)
BABA   68.78 (-0.15%)
T   16.38 (+0.31%)
F   12.16 (+0.83%)
MU   109.98 (-1.74%)
GE   152.66 (-0.18%)
CGC   8.20 (+4.73%)
DIS   111.97 (-0.41%)
AMC   3.12 (+6.85%)
PFE   25.40 (+0.04%)
PYPL   62.12 (+0.03%)
XOM   120.10 (+1.33%)
S&P 500   5,000.83 (-0.21%)
DOW   37,915.40 (+0.37%)
QQQ   420.87 (-0.60%)
AAPL   165.35 (-1.01%)
MSFT   402.51 (-0.44%)
META   491.71 (-2.01%)
GOOGL   154.77 (-0.79%)
AMZN   177.68 (-0.86%)
TSLA   148.64 (-0.86%)
NVDA   838.49 (-0.97%)
AMD   152.74 (-1.51%)
NIO   3.87 (-3.25%)
BABA   68.78 (-0.15%)
T   16.38 (+0.31%)
F   12.16 (+0.83%)
MU   109.98 (-1.74%)
GE   152.66 (-0.18%)
CGC   8.20 (+4.73%)
DIS   111.97 (-0.41%)
AMC   3.12 (+6.85%)
PFE   25.40 (+0.04%)
PYPL   62.12 (+0.03%)
XOM   120.10 (+1.33%)
S&P 500   5,000.83 (-0.21%)
DOW   37,915.40 (+0.37%)
QQQ   420.87 (-0.60%)
AAPL   165.35 (-1.01%)
MSFT   402.51 (-0.44%)
META   491.71 (-2.01%)
GOOGL   154.77 (-0.79%)
AMZN   177.68 (-0.86%)
TSLA   148.64 (-0.86%)
NVDA   838.49 (-0.97%)
AMD   152.74 (-1.51%)
NIO   3.87 (-3.25%)
BABA   68.78 (-0.15%)
T   16.38 (+0.31%)
F   12.16 (+0.83%)
MU   109.98 (-1.74%)
GE   152.66 (-0.18%)
CGC   8.20 (+4.73%)
DIS   111.97 (-0.41%)
AMC   3.12 (+6.85%)
PFE   25.40 (+0.04%)
PYPL   62.12 (+0.03%)
XOM   120.10 (+1.33%)
Free Trial
OTCMKTS:BLUSF

BELLUS Health (BLUSF) Stock Price, News & Analysis

→ I’m officially sounding the alarm. (From Altimetry) (Ad)
Free BLUSF Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
N/A
50-Day Range
$6.46
▼
$14.51
52-Week Range
N/A
Volume
3.45 million shs
Average Volume
39,610 shs
Market Capitalization
$2.35 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
BLUSF stock logo

About BELLUS Health Stock (OTCMKTS:BLUSF)

BELLUS Health, Inc. is a biopharmaceutical development company, which engages in the research and development of products that provide health solutions and address critical unmet medical needs. Its products include BLU-5937, KIACTA, AMO-01, and ALZ-801. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.

BLUSF Stock News Headlines

April 15, 2024 | msn.com
This Viral Powder Blush Will Make You Give Up Your Creams
April 13, 2024 | yahoo.com
If You Only Use 1 Blush for the Rest of Your Life, It Should Be This Powder-Cream Duo
April 19, 2024 | Altimetry (Ad)
I’m officially sounding the alarm.
AI has been the hottest financial story of 2023. And rightly so – AI stocks have beat the broader market by over 62%. But right now, my system is warning me that many AI stocks are riding higher on hype alone.
November 8, 2023 | morningstar.com
Natura &Co Holding SA ADR NTCO
October 24, 2023 | health.usnews.com
Raymond R. Blush
June 16, 2023 | benzinga.com
BELLUS Health Inc. Announces Voting Results from Special Meeting of Shareholders
May 12, 2023 | msn.com
BELLUS Health: Q1 Earnings Insights
April 19, 2023 | markets.businessinsider.com
Where BELLUS Health Stands With Analysts
April 19, 2024 | Altimetry (Ad)
I’m officially sounding the alarm.
AI has been the hottest financial story of 2023. And rightly so – AI stocks have beat the broader market by over 62%. But right now, my system is warning me that many AI stocks are riding higher on hype alone.
April 18, 2023 | msn.com
GSK to Buy Bellus for $2 Billion to Gain Cough Medicine
April 5, 2023 | seekingalpha.com
Bellus Health posts proof-of-concept data for cough candidate
April 5, 2023 | markets.businessinsider.com
BELLUS: Phase 1 Study Establishes Proof Of Concept For Developing ER Formulation Of Camlipixant
April 5, 2023 | markets.businessinsider.com
BELLUS: Phase 1 Study Establishes Proof Of Concept For Developing ER Formulation Of Camlipixant
November 14, 2022 | benzinga.com
BELLUS Health Reports Third Quarter 2022 Financial Results and Business Highlights
November 14, 2022 | msn.com
Bellus Health (BLU) Reports Q3 Loss, Misses Revenue Estimates
October 10, 2022 | yahoo.com
BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the CHEST Annual Meeting
July 18, 2022 | benzinga.com
BELLUS Health Closes US$153 Million Public Offering of Common Shares in Canada and the United States
March 10, 2022 | gurufocus.com
Power Corp of Canada Buys BELLUS Health Inc, Sells Alibaba Group Holding, New Oriental ...
February 17, 2022 | gurufocus.com
First Light Asset Management, LLC Buys AtriCure Inc, Keros Therapeutics Inc, BELLUS Health Inc, ...
September 13, 2021 | benzinga.com
What's Going On With BELLUS Health's Stock Today?
See More Headlines
Receive BLUSF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BELLUS Health and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/08/2019
Today
4/19/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
N/A
Sub-Industry
N/A
Current Symbol
OTCMKTS:BLUSF
CUSIP
N/A
CIK
N/A
Web
www.bellushealth.com
Phone
45-0680-4500
Fax
N/A
Employees
10
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($0.10)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-7,010,000.00
Net Margins
-49,910.34%
Pretax Margin
N/A
Return on Equity
-48.37%
Return on Assets
-45.25%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
13.87
Quick Ratio
13.87

Sales & Book Value

Annual Sales
$30,000.00
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.25 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
159,117,000
Free Float
N/A
Market Cap
$2.35 billion
Optionable
Not Optionable
Beta
1.55
7 Stocks to Own Before the 2024 Election Cover
7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Roberto Bellini
    President, Chief Executive Officer & Director
  • François Desjardins
    Vice President-Finance
  • Denis Garceau
    Senior Vice President-Drug Development
  • Tony Matzouranis
    Vice President-Business Development
  • Sébastien Roy
    Secretary

Key Competitors

View All Competitors

BLUSF Stock Analysis - Frequently Asked Questions

How were BELLUS Health's earnings last quarter?

BELLUS Health Inc (OTCMKTS:BLUSF) released its quarterly earnings results on Wednesday, May, 8th. The company reported ($0.02) EPS for the quarter, missing analysts' consensus estimates of ($0.01) by $0.01. The firm had revenue of $0.01 million for the quarter. BELLUS Health had a negative trailing twelve-month return on equity of 48.37% and a negative net margin of 49,910.34%.

This page (OTCMKTS:BLUSF) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
Biden’s $374B Giveaway Into This Sector
DTI
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
Paradigm Press
The #1 Crypto for 2024
InvestorPlace
He Is Giving Away Bitcoin
Crypto Swap Profits
Your Money is Not Safe
American Alternative